Pancreatic cancer is the kind of diagnosis that stops time. Whether you’ve heard it from a doctor yourself, watched a family member receive it, or followed a colleague’s quiet, difficult year after it, you know that the words land differently than almost any other cancer news. There’s a particular helplessness that settles in around it — a sense that the medical system has simply run out of good options. For decades, that feeling has been largely justified. Treatments have been punishing, and the results have often been modest.
But April 2026 has brought something genuinely different to the conversation. Not one, but two experimental drugs have produced survival data that oncologists are describing in terms rarely used for this disease. The science behind at least one of them took nearly 40 years to figure out. And the drug regulators are paying close attention.
Here’s what the research actually shows — and what it means if you or someone you love is navigating this disease right now.
Why Pancreatic Cancer Is So Hard to Beat
To understand why these new results matter so much, it helps to know what researchers have been up against.
According to the American Cancer Society’s Cancer Statistics 2025 report, the five-year relative survival rate for pancreatic cancer sits at 13%, and just 8% for people diagnosed with pancreatic adenocarcinoma — the most common form. A decade ago, that number was 6%, so progress has been made, but it has been slow and uneven. While overall cancer mortality is falling across other tumor types, pancreatic cancer remains the third-leading cause of cancer-related deaths in the United States and appears on track to become the second-leading cause in the coming years.
The numbers at the advanced stage are especially sobering. In 2025, approximately 66,440 individuals in the United States were diagnosed with pancreatic cancer, with an estimated 51,750 deaths expected from the disease. Stage IV pancreatic cancer carries a five-year survival rate of just 3.2%, and the average patient diagnosed at that late stage lives for about one year after diagnosis. Those figures explain why every gain — even a matter of months — carries enormous weight in this field.
The core problem is that pancreatic cancer usually shows little or no symptoms until it has advanced and spread. Approximately 80% of pancreatic ductal adenocarcinoma (PDAC — the full name for the most common type) patients are diagnosed at an advanced or metastatic stage precisely because of that silent progression. By the time most people know something is wrong, the window for surgery has often already closed.
The Genetic Target Scientists Spent Decades Trying to Hit
A gene called KRAS sits at the center of why pancreatic cancer is so resistant to treatment — and at the center of why the new drugs are so exciting.
When genes like KRAS function normally, they act like stop-and-go signals for healthy cell activity. But when KRAS mutates, it’s as if the signal gets stuck on “go,” driving the uncontrolled growth of cancer cells. According to a 2020 review in Nature Reviews Clinical Oncology, KRAS mutations drive about 11% of all cancers — but pancreatic cancers are the most dependent on KRAS, with more than 90% of pancreatic ductal adenocarcinomas harboring a KRAS mutation.
Identified in 1982 as the first gene shown to be aberrantly activated in human cancer, KRAS has been the focus of intensive drug discovery efforts for decades — and was widely considered “undruggable.” The structural reason for this is technical but worth understanding: the KRAS protein lacks the kind of binding pockets that small-molecule drugs can grab onto. In other words, there was nowhere for a drug to attach.
It took nearly 40 years until the first direct KRAS inhibitors, targeting a specific mutation called G12C, were clinically approved — initially for certain lung cancers. But G12C is rare in pancreatic cancer, appearing in only about 1-2% of pancreatic tumors, so those earlier drugs haven’t meaningfully changed pancreatic cancer care. The far bigger need has always been for drugs targeting the mutations most common in PDAC — and that’s exactly what daraxonrasib was designed to do.
What Daraxonrasib Does — and Why It’s Different
Daraxonrasib, developed by Revolution Medicines, isn’t limited to a single KRAS mutation. It functions as a pan-RAS inhibitor — meaning it works across multiple forms of the mutation simultaneously.
The FDA granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic pancreatic ductal adenocarcinoma harboring G12 mutations. More than 90% of pancreatic cancer patients harbor tumors driven by RAS protein mutations, making pancreatic cancer the most RAS-addicted of all major cancers. That’s why the drug’s broad targeting capability matters so much — it’s potentially relevant to the vast majority of people with this disease, not just a narrow genetic subset.
The mechanism works by locking the growth signal that the mutated RAS protein sends, causing cancer cells to slow or stop proliferating — a process called RAS inhibition. Daraxonrasib has shown activity against several different forms of RAS mutations, including G12D, G12V, G12R, and Q61X mutations. Among KRAS mutations in pancreatic cancer, 40% are G12D, 29% are G12V, and 15% are G12R — all targets that daraxonrasib can address. That breadth of coverage is a meaningful departure from earlier targeted therapies.
The Phase 1 Trial Results
Before the landmark Phase 3 data arrived in April 2026, earlier trial results had already signaled something unusual was happening.
In the Phase 1 trial, among 22 patients with second-line metastatic PDAC and KRAS G12X mutations receiving daraxonrasib at 300 mg per day, the median progression-free survival — the length of time the cancer didn’t grow or spread — was 8.8 months. At that dose in the KRAS G12X-mutant population, the objective response rate was 36% and the disease control rate was 91%.
A 91% disease control rate, meaning nearly all patients saw their cancer either shrink or stabilize, is a number that stands out sharply against the backdrop of a disease that typically resists most interventions. These early results were encouraging enough to push the program into a full global Phase 3 trial. One particularly important aspect: daraxonrasib is taken orally, once a day — a meaningful quality-of-life difference for patients who can’t tolerate intravenous chemotherapy.
The Phase 3 Results: A 60% Reduction in the Risk of Death
The numbers that arrived in April 2026 were unlike anything the field has seen for this cancer in years.
In the Phase 3 RASolute 302 trial, daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for standard chemotherapy in the intent-to-treat population — a 60% reduction in the risk of death (hazard ratio 0.40, p <0.0001). To translate that plainly: patients on daraxonrasib lived nearly twice as long as those receiving the current standard of care. The statistical strength of the result means the odds that this finding happened by chance are extraordinarily small.
Oncologists are describing this as a new era for pancreatic cancer medicine. Revolution Medicines intends to submit a New Drug Application to the FDA based on the RASolute 302 results, and daraxonrasib has been selected for the FDA Commissioner’s National Priority Voucher pilot program — an initiative designed to accelerate review of therapies aligned with U.S. national health priorities. Dana-Farber Cancer Institute’s Brian M. Wolpin, the principal investigator for the trial, called the results “a clear and highly meaningful step forward” for patients with previously treated metastatic pancreatic cancer.
A Second Drug Is Also Improving Survival
Daraxonrasib isn’t the only drug producing striking results in April 2026. A second experimental therapy, elraglusib, has shown its own meaningful numbers through a completely different mechanism.
Elraglusib, developed at Northwestern University, is an inhibitor of GSK-3β — a protein involved in controlling how cancer cells grow and how tumors suppress immune response. Where daraxonrasib targets the genetic mutation driving tumor growth, elraglusib targets the protective environment that pancreatic tumors build around themselves, helping immune cells and chemotherapy better reach the cancer.
In a randomized phase 2 clinical trial published in Nature Medicine in April 2026, patients who received elraglusib alongside standard chemotherapy were twice as likely to be alive after one year compared to those receiving chemotherapy alone — 44% versus 22%. About 13% of patients in the elraglusib group were alive at two years, compared to none in the chemotherapy-only group. The trial enrolled 233 patients with metastatic pancreatic cancer across 60 sites in six countries. Overall, elraglusib reduced the risk of death by 38% compared to chemotherapy alone, according to the Northwestern Medicine research team.
The two-year figure is particularly striking: zero survivors at two years in the chemotherapy group, versus 13% in the elraglusib group. The study is one of only a few successful randomized trials in the last decade to show a survival benefit applicable to a broad population of pancreatic cancer patients. A phase 3 trial is now being planned.
Could These Drugs Be Used Together?
Researchers are already thinking about what happens when you combine them.
Actuate Therapeutics, the company behind elraglusib, launched a strategic research initiative in March 2026 to study combining elraglusib with RAS inhibitors — a direct nod toward the possibility that these two drugs, attacking pancreatic cancer from different angles, might produce compounding benefit. The biological rationale is straightforward: daraxonrasib slows the genetic engine driving tumor growth, while elraglusib dismantles the tumor’s defensive wall. Using both simultaneously could make cancer cells more vulnerable from multiple directions at once.
This isn’t just theoretical optimism. The field of oncology has repeatedly shown that combination approaches — targeting different vulnerabilities of the same cancer — often outperform single agents. The prospect of combining a pan-RAS inhibitor like daraxonrasib with elraglusib or other novel agents is now being treated as a serious research priority, not a distant hypothetical.
For more on emerging treatments targeting cancer, see more coverage from The Hearty Soul.
What This Means for You
If you or someone close to you is navigating a pancreatic cancer diagnosis, the practical takeaway from April 2026 is this: the treatment conversation is changing, and it’s worth having a specific, informed conversation with your oncologist about what’s available now and what’s coming.
First, ask about biomarker testing. The Pancreatic Cancer Action Network strongly recommends that all pancreatic cancer patients get biomarker testing of their tumor tissue. This testing can tell you whether you have a KRAS mutation and which specific variant your tumor carries — information that matters right now because daraxonrasib’s trials specifically targeted patients with KRAS G12 mutations. Knowing your biomarker status can determine whether you qualify for one of the targeted clinical trials now enrolling.
Second, don’t wait for FDA approval to ask about clinical trial access. The NDA for daraxonrasib hasn’t been filed yet, but trials are running. Patients who qualify can access these drugs now through enrollment. Up-to-date listings are available at ClinicalTrials.gov. If your current oncologist isn’t discussing targeted therapies or clinical trials, a second opinion at a major cancer center with an active gastrointestinal oncology program is a reasonable and often rewarded step.
None of these drugs are cures. Researchers are clear about that. But the gap between “no good options” and “drugs that can nearly double survival” is not a small one. For a disease that has been this resistant for this long, the results arriving in spring 2026 represent a genuine inflection point — and patients and their families deserve to know it exists.
Medical Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice because of something you have read here.
A.I. Disclaimer: This article was created with AI assistance and edited by a human for accuracy and clarity.
Read More: New Treatment Triggers Self-Destruction of Pancreatic Cancer Cells Within a Month